Glenmark Pharmaceuticals share news, announcements and annual reports
NSE: GLENMARKBSE: 532296Pharmaceuticals & BiotechnologyMid Cap
Glenmark Pharmaceuticals Limited · Face value ₹1 Face value. The nominal value of one share as the company issued it, the unit its share capital is counted in and a dividend can be stated as a percentage of; it has no link to the share price. Face value in the glossary · Listed Feb 2000
Last close ₹2,382.00up ₹83.30 (3.62%)BSE ₹2,388.00
Share price at the NSE close on 2 Nov 2026. Previous close ₹2,298.70.
2 Nov: open ₹2,306.00, high ₹2,400.10, low ₹2,306.00
52-week range of traded prices to 2 Nov 2026
₹1,801.40Low, 7 Nov 2025₹2,537.60High, 28 Aug 2026
- Next results date: the board meets on 5 Nov 2026 to consider: financial results. The notice · Results calendar
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies. Market capitalisation: how it is worked out
- ₹67,226 Cr176th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- 37.39
- P/E without one-offsPrice to earnings without one-off items. Market cap divided by core profit: the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, less one-off items (exceptional items and the result of businesses sold or closed). Shown where the one-off items move that profit by more than a tenth. The last twelve months' profit includes −₹1,943 crore of one-off items, the largest of them in the quarter to Sep 2025.
- 17.97
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Price to book: how it is worked out
- 6.40
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- 0.11%
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it.
- 18.6%
- ROE without one-offsReturn on equity without one-off items. Core profit, the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders less one-off items (exceptional items and the result of businesses sold or closed), as a percentage of the same net worth as the return on equity. Shown where the one-off items move that profit by more than a tenth. The last twelve months' profit includes −₹1,943 crore of one-off items, the largest of them in the quarter to Sep 2025.
- 38.6%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet.
- 39.8%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026.
- 0.00
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day. Volume in the glossary
- 15,49,67347.5% delivered
Glenmark Pharmaceuticals share news and announcements
1,381 announcements, routine notices left out, newest first. Page 16 of 28.
Jun 2016
May 2016
9 May · Updates
Apr 2016
Mar 2016
Feb 2016
Jan 2016
25 Jan · Regulation 44(3) of SEBI (LODR), Reg., 2015
5 Jan · Legal
Exchange had sought clarification from Glenmark Pharmaceuticals Limited with respect to recent news item captioned "Roche, Glenmark Settle Patent suit over cancer drug". The Company, has vide email dated January 04, 2016 has submitted that Glenmark confirms that it has reached an agreement with Roche/OSI regarding ongoing patent disputes relating to the anti-cancer medicine - Erlotinib Hydrochloride. As part of the agreement, the companies have ceased all relevant patent litigation on this product. The settlement is a part of normal course of our business and it will have no material impact on the company.4 Jan · Legal
Exchange has sought clarification from Glenmark Pharmaceuticals Limited with respect to recent news item captioned "Roche, Glenmark Settle Patent suit over cancer drug' . In this regard, Exchange have advised the Company to provide clarification/confirmation on the news item in detail including the following: a) Whether such event/negotiations/article stated in published news were taking place? If so, you are advised to provide the said information along with the sequence of events in chronological order and the material impact of this article on the Company. b) Whether company are aware of any information that has not been announced to the Exchanges under regulation 30 of Listing regulations. The response from the Company is awaited.
Dec 2015
24 Dec · Meeting
Nov 2015
Oct 2015
29 Oct · Board meeting
29 Oct · News Verification
Exchange has sought clarification from Glenmark Pharmaceuticals Limited, with respect to recent news item captioned "Setback For Glenmark: Sanofi Not To Pursue Development Of Vatelizumab Molecule". In this regard, the Exchange has advised the Company to provide clarification/confirmation on the news item in detail including the following: a) Whether such negotiations were taking place and b) Whether you/company are aware of any information that has not been announced to the Exchanges which could explain the aforesaid movement in the trading. The response from the company is awaited.